No products in the cart.
Most SARMs are non-steroidal compounds that mimic testosterone without being built like a steroid. YK-11 is different. It is structurally a steroid, classified as a SARM, and behaves like neither cleanly. That unusual position is why it has attracted serious research attention and growing popularity in UK gyms. Here is what the science actually says, what makes YK-11 unlike anything else, and what risks most users are not fully accounting for.
What Is YK-11 and Why Is It Different from Other SARMs?
YK-11 was first synthesized in 2011 by Japanese scientist Yuichiro Kanno and studied as a partial androgen receptor agonist. Most SARMs are non-steroidal molecules that bind androgen receptors without a steroid backbone. YK-11 is built on a steroidal scaffold, making it structurally far closer to traditional anabolic steroids than to compounds like Ostarine or Ligandrol.
A 2026 study in the International Journal of Molecular Sciences tested YK-11 across five hormone receptors: androgen, estrogen, progesterone, glucocorticoid, and mineralocorticoid. It found strong predicted binding across all five. The receptor affinity order was glucocorticoid greater than progesterone greater than androgen receptor. That is not the profile of a selective compound. It behaves like a steroid at the receptor level.
How Does YK-11 Work in the Body?
YK-11 works through two mechanisms, which is what makes it stand out.
Androgen receptor activation. YK-11 binds androgen receptors as a partial agonist, stimulating muscle growth-related gene expression. In cell studies it showed greater anabolic potency than DHT, the most powerful naturally occurring androgen.
Myostatin inhibition. Myostatin is a protein that limits how big muscles can grow. YK-11 triggers follistatin production, which binds to myostatin and suppresses it, removing that natural ceiling. Kanno’s 2013 study confirmed this mechanism in muscle cell cultures.
No other available compound combines both pathways through a single mechanism. That is the biological reason behind YK-11’s reputation for being exceptionally potent.
What Does the Research on YK-11 Actually Show?
The research base is almost entirely preclinical.
- Cell studies confirm androgen receptor binding, follistatin upregulation, myostatin inhibition, and increased bone-building cell activity
- A 2021 animal study found YK-11 reduced muscle wasting caused by sepsis
- No human clinical trial has ever tested YK-11 for any purpose
Every effect attributed to it in bodybuilding is extrapolated from cell studies and animal models. There is no confirmed human dose range, no pharmacokinetic data, and no long-term safety profile in humans.
Does YK-11 Damage the Brain and Liver?
This is the most underreported part of the YK-11 research.
A 2025 study found YK-11 significantly altered brain chemistry in the hippocampus, impairing memory consolidation. The compound crosses the blood-brain barrier easily. The same study found YK-11 promotes oxidative stress in cells, which can lead to DNA damage.
A 2024 ScienceDirect study on YK-11 and liver cells found raised levels of ALT, a liver damage marker, alongside cell death indicators. This adds liver toxicity to the risk list, which is significant for a compound many users assume is safer than oral steroids.
The 2026 MDPI docking study also flagged a concern about the glucocorticoid receptor. YK-11 predicted to bind it as strongly as cortisol. This raises the possibility of off-target effects including metabolic disruption, adrenal stress, and mood changes.
How Much Does YK-11 Suppress Natural Testosterone?
More than most SARMs, based on its androgen receptor potency and steroidal structure. Less than a full steroid cycle is the general expectation, but this is inference rather than confirmed data.
YK-11 will suppress LH and FSH like other androgens. Experienced users consistently report that PCT is mandatory, not optional. Health Canada specifically warned that YK-11 can cause heart attack, stroke, and liver damage, with long-term effects unknown.
Nolvadex or Clomid after a YK-11 cycle is the standard recommendation. Skipping PCT carries the same risks as coming off a traditional steroid cycle without support.
Does YK-11 Actually Build More Muscle Than Other SARMs?
The myostatin inhibition mechanism is real at the cellular level. Whether it translates to meaningful additional muscle in humans is unknown.
Myostatin-deficient animals and rare humans are dramatically more muscular, which confirms the pathway matters. But dedicated myostatin inhibitors tested in clinical trials have generally produced disappointing results. The biology is sound. Whether YK-11 delivers the benefit in practice, and at what health cost, has not been tested in humans.
How Does YK-11 Compare to Regular SARMs?
YK-11 sits in its own category for three clear reasons:
- Its steroidal structure means it binds multiple hormone receptors, not just the androgen receptor, unlike non-steroidal SARMs
- Its dual mechanism combining androgen activation and myostatin inhibition has no equivalent in other SARMs or steroids
- Its risk profile includes neurological and liver toxicity data not seen with compounds like Ostarine or Ligandrol
Treating it as a mild SARM alternative to steroids misrepresents what it actually is.
Is YK-11 Legal in the UK?
Personal possession is not a criminal offence. YK-11 is not listed under the Misuse of Drugs Act 1971.
Selling it for human use is illegal under the Human Medicines Regulations 2012 and FSA novel food rules. It has no MHRA approval and no legal prescription pathway.
WADA bans it under S1 Anabolic Agents. A positive test carries the same consequences as a steroid violation. The detection window for steroidal compounds can extend well beyond the last dose.
FAQs
Is YK-11 a steroid or a SARM? Both structurally. It has a steroidal backbone and was studied as a SARM. The 2026 MDPI research confirmed it binds multiple steroid hormone receptors, not just androgen receptors. It is more accurately described as a steroidal SARM-like compound.
Does YK-11 need PCT? Yes, always. Its androgen receptor potency and steroidal nature cause meaningful testosterone suppression. Most users report needing Nolvadex or Clomid to recover properly.
Is YK-11 riskier than other SARMs? Based on the available research, yes. The neurological data, liver toxicity findings, and broad receptor binding profile put it in a higher risk category than non-steroidal SARMs like Ostarine.
Can YK-11 damage memory? A 2025 animal study found it impaired memory consolidation by altering brain chemistry in the hippocampus. This has not been confirmed in humans but is a documented preclinical finding.
Conclusion
YK-11 is not a standard SARM. The steroidal structure, dual mechanism, high brain permeability, and broad receptor binding make it pharmacologically complex and poorly understood compared to what most users assume. The muscle-building science is interesting. The neurological and liver findings are a serious concern that the compound’s growing popularity in UK gyms has not yet caught up with. No human trial data exists. That gap matters more than the gym talk suggests.
